Increasing prevalence of obesity has led to an upsurge in demand for
anti-obesity prescription drugs globally. In addition, increasing
level of chronic stress is also expected to impact the global market
growth of anti-obesity prescription drugs positively. Transparency
Market Research states that the global anti-obesity prescription
drugs market is projected to reflect a CAGR of 4.8% over the forecast
period, 2017-2026.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=34835
Growth of the global anti-obesity prescription drugs market is mainly
bound by various macro-economic and micro-economic factors.
Increasing consumption of unhealthy food and beverage products is
projected to rev up demand for anti-obesity prescription drugs
globally. As the unhealthy food products are rich in cholesterol,
surge in consumption of unhealthy food and beverage products continue
to increase obesity.
Obesity has continued to remain a major side-effect of consuming
psychotropic drugs. Consumption of various antidepressant drugs
stimulates hunger in the patients. Due to appetite stimulating
features of various antidepressant drugs, patients tend to consume
more food products. Moreover, diabetic drugs such as
thiazolidinediones, sulfonylureas and insulin are also appetite
stimulating drugs. Side-effects related to the consumption of these
drugs is projected to increase obesity. Increasing side-effects of
obesity is projected to increase demand for obesity management
globally. Consumption of diabetic and psychotropic drugs are expected
to impact the global market growth of anti-obesity prescription drugs
positively.
Moreover, surge in the level of chronic stress is projected to boost
demand for the obesity management services. Growing level of chronic
stress leads people to eat unhealthy food to counter the physical and
emotional stress. Moreover, long-term stress due to the emotional and
physical pressure leads to the release of cortisol hormones by the
brain. Release of cortisol hormones further stimulates the appetite
of the people. Eating disorders due to increasing level of chronic
stress is further expected to rev up demand for obesity management.
Bound to these factors, the global market of anti-obesity
prescription drugs is projected to represent significant growth
during the forecast period.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=34835
However, the global market of anti-obesity prescription drugs will
continue to witness inhibiting growth bound to various factors.
Practicing yoga is becoming a popular exercise for weight reduction
and hypertension. Increasing preference for practicing yoga to lose
weight has led to reduced reliance of obese population on
anti-obesity medications. Moreover, the obese persons prefer
including sugar-free food and beverages in their diet plan. These
factors are projected to inhibit the global market growth of
anti-obesity prescription drugs.
As patients of high blood and sugar levels are more prone to the risk
of obesity, doctors are increasingly prescribing liraglutide
medicines. Based on the drug class, the liraglutide segment is
projected to generate significant revenues, representing more than
US$ 100 Mn by 2026-end. In contrary to this, the bupropion and
naltrexone drug class segment is projected to reflect a significant
CAGR through 2022. In terms of revenue, the adult age group segment
is projected to account for more than US$ 100 Mn by 2017-end. This
segment is projected to witness a robust CAGR in the global market of
anti-obesity prescription drugs during the forecast period. By
2026-end, the hospital pharmacies distribution channel segment will
continue to witness the fastest growth, accounting for more than US$
100 Mn.
Major players in the global market of anti-obesity prescription drugs
include Orexigen Therapeutics, Inc, F Hoffmann La Roche Ltd, VIVUS,
Inc, Novo Nordisk A/S and Arena Pharmaceuticals, Inc.
Report Overview @
https://www.transparencymarketresearch.com/antiobesity-prescription-drugs-market.html
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment